Tissue Regenix Group PLC Move to Electronic Reporting (6881O)
February 11 2021 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 6881O
Tissue Regenix Group PLC
11 February 2021
Tissue Regenix Group plc
Move to Electronic Reporting
("Tissue Regenix" or the "Company")
Leeds, 11 February 2021 - Tissue Regenix Group (AIM:TRX) the
regenerative medical devices company announces that it has written
to all registered shareholders regarding its intention to adopt
electronic communication methods for shareholder documents.
Tissue Regenix is seeking to adopt electronic communication in
order to improve the Company's environmental sustainability efforts
and ensure timely and cost-effective communications with all
shareholders.
A letter has been posted to all registered shareholders from the
Company's registrar, Link Group, and a copy of this letter will
also be made available on the Company's website.
Shareholders wishing to continue to receive shareholder
documents in printed form will need to notify Link Group no later
than 10 March 2021 by completing and returning the response form
within the letter, or through registering for a shareholder account
on: www.signalshares.com
Those shareholders who do not return the response form will be
deemed to have consented to receiving shareholder documents or
information (including the annual report and notices of Company
meetings) by means of the Tissue Regenix Group website:
www.tissueregenix.com
A notice via email or mail, subject to the shareholder
preference identified, will be sent to shareholders when new
materials are available online including the annual report.
Shareholders are entitled to change their preference of
communication at any time in the future.
For more Information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke Chief Financial Officer Via Walbrook PR
------------------------------------------ ------------------------------
Stifel Nicolaus Europe Limited (Nominated Tel: +44 (0)207 710
Adviser and Broker) 7600
Ben Maddison / Alex Price
------------------------------------------ ------------------------------
Walbrook PR Ltd Tel: +44 (0)20 7933
Paul McManus / Alice Woodings / Lianne 8780
Cawthorne TissueRegenix@walbrookpr.com
------------------------------------------ ------------------------------
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPURPPUPGGRU
(END) Dow Jones Newswires
February 11, 2021 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024